Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.39 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13245960 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1GAAMAPK1PKM | |
| SCHEMBL2989363 | 0.88 | PKM (0.41) | ALDH1A1GAAPKMMAPTKMT2A | |
| SCHEMBL13245961 | 0.88 | PKM (0.41) | ALDH1A1GAAPKMMAPTKMT2A | |
| SCHEMBL13245962 | 0.80 | PKM (0.46) | ALDH1A1PKMMAPTTSHRHPGD | |
| SCHEMBL2989019 | 0.80 | PKM (0.46) | ALDH1A1PKMMAPTTSHRHPGD | |
| SCHEMBL3549948 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1GAAMAPK1MAPT | |
| SCHEMBL3549945 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1GAAMAPK1MAPT | |
| SCHEMBL30267353 | 0.79 | ALDH1A1 (0.47) | ALDH1A1PKMMAPTKMT2AELOVL6 | |
| SCHEMBL15152644 | 0.78 | L3MBTL1 (0.47) | MAPK1PKMMAPTKMT2AELOVL6 | |
| SCHEMBL15152645 | 0.78 | L3MBTL1 (0.47) | MAPK1PKMMAPTKMT2AELOVL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173958-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| EP-2032547-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007141545-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173958-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | DGAT1, DGAT2, ACAT2 | KDM4E 3354/4885ALDH1A1 142/4885GAA 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.